Clinical trial · Interventional
Focal Ablation of Cervical Precancer
Focal Ablation of High-grade Cervical Intraepithelial Neoplasia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a pilot cohort study of women undergoing focal ablation for high-grade cervical intraepithelial neoplasia (HGCIN). The cohort was recruited from the UCSF Dysplasia Clinics. The standard treatment involves treatment of the entire cervix. Women with HGCIN meeting inclusion criteria were recruited for enrollment into the pilot study of focal treatment. Upon enrollment, they underwent focal ablational treatment rather than standard ablational treatment of the cervix. Follow-up visits were conducted at 2 weeks and 6 months to assess safety, feasibility, and acceptability. The 6-month recurrence rate of HGCIN will be calculated.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| High-grade Cervical Intraepithelial Neoplasia | High Grade Cervical Intraepithelial Neoplasia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Focal treatment | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Focal treatment arm
- interventionNames
- Procedure: Focal treatment
Primary outcomes (1)
- measure
- Six-month recurrence rate of high-grade cervical intraepithelial neoplasia
- timeFrame
- six months
Secondary outcomes (3)
- measure
- Safety of focal treatment
- timeFrame
- six months
- description
- Participants will be asked to report any adverse events following focal treatment. These events will be graded according to standard criteria (DAIDS).
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 21 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * Age 21-45 yo * Biopsy-confirmed high grade cervical intraepithelial neoplasia grade 2, 3, or 2/3 * Satisfactory colposcopy, i.e., the entire transformation zone is visible * Lesion occupying \<= 2 quadrants of the cervix. Exclusion Criteria: * Unsatisfactory colposcopy. * Colposcopic lesion extending into the endocervical canal beyond colposcopic visualization. * Endocervical curettage positive for high-grade cervical intraepithelial neoplasia. * Suspicion for invasive cancer on colposcopic exam. * Glandular dysplasia or atypical glandular cells on cytology. * Unreliable for follow-up. * Immunosuppression (HIV, transplant recipient, etc.)
References
Publications (0)
Data not yet available